A new look at evaluating MTD designs in cancer research
From MaRDI portal
Publication:2431683
DOI10.1080/15598608.2009.10411930zbMATH Open1211.62189OpenAlexW2059268290MaRDI QIDQ2431683FDOQ2431683
Authors: L. T. Tremmel 
Publication date: 18 April 2011
Published in: Journal of Statistical Theory and Practice (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/15598608.2009.10411930
Recommendations
- Design and Analysis of Phase I Clinical Trials
- The treatment versus experimentation dilemma in dose finding studies
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
- An assessment of up- and down designs and associated estimators in phase I trials
- A method based on isotonic regression estimation for identifying the maximum tolerated dose
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50) Nonparametric inference (62G99)
Cites Work
Cited In (10)
- The treatment versus experimentation dilemma in dose finding studies
- An assessment of up- and down designs and associated estimators in phase I trials
- Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
- Design and Analysis of Phase I Clinical Trials
- Adaptive clinical trial designs for phase I cancer studies
- Sequential designs for dose escalation studies in oncology
- The role of minimal sets in dose finding studies
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
- A method based on isotonic regression estimation for identifying the maximum tolerated dose
This page was built for publication: A new look at evaluating MTD designs in cancer research
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2431683)
